Trevi Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview

Trevi Therapeutics

05/08/2025 21:50

Trevi Therapeutics Inc TRVI.OQ TRVI.O is expected to  show no change in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

​LSEG's mean analyst estimate for Trevi Therapeutics Inc is for a loss of 10 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Trevi Therapeutics Inc is $22.00, about 66% above its last closing price of $7.49

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.12
-0.12
-0.09
Beat
25.7
Dec. 31 2025
-0.12
-0.12
-0.11
Beat
7.5
Sep. 30 2024
-0.12
-0.12
-0.13
Missed
-9.8​
Jun. 30 2024
-0.10
-0.11
-0.12
Missed
-13.2
​​Mar. 31 2024
-0.09
-0.09
-0.11
Missed
-25
Dec. 31 2023
-0.09
-0.08
Beat
12.7​
Sep. 30 2023
-0.09
-0.09
-0.08
Beat
12.7
Jun. 30 2023
-0.09
-0.08
-0.07
Beat
17.6

This summary was machine generated August 5 at 20:50 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)